Targeting cistrome and dysregulated transcriptome of post-MPN sAML

Abstract

Pathogenic mutations in JAK2, MPL or calreticulin associated with activated JAK/STAT3/5 signaling are a common feature in Myeloproliferative Neoplasms (MPNs) [1]. Pivotal clinical trials confirmed the activity, leading to FDA approval, of the type I JAK1/2 inhibitor ruxolitinib as therapy for advanced MPN-Myelofibrosis (MF) and Polycythemia Vera [1… (More)
DOI: 10.18632/oncotarget.21752

Topics

1 Figure or Table